Shares of Moderna Inc. MRNA, +2.71% gained 3.4% in trading on Monday after the company said it received full approval from the Food and Drug Administration for its COVID-19 vaccine, which is now called Spikevax. The FDA has granted full approval to one other COVID-19 shot: BioNTech SE BNTX, +3.21% and Pfizer Inc.’s PFE, -3.33% Comirnaty. The Spikevax approval is for adults, though the vaccine still has emergency authorization for use in teens and as a booster dose. Moderna’s stock is down 4.5% over the past year, while the broader S&P 500 SPX, +0.65% is up 17.0%.
This article was originally published by Marketwatch.com. Read the original article here.
